The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Current Status of Platinum-Based Antitumor Drugs
Abstract
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTCurrent Status of Platinum-Based Antitumor DrugsErnest Wong and Christen M. GiandomenicoView Author Information AnorMed Incorporated, 200-20353 64th Avenue, Langley, British Columbia, Canada V2Y 1N5 Cite this: Chem. Rev. 1999, 99, 9, 2451–2466Publication Date (Web):August 17, 1999Publication History Received22 February 1999Revised14 June 1999Published online17 August 1999Published inissue 8 September 1999https://pubs.acs.org/doi/10.1021/cr980420vhttps://doi.org/10.1021/cr980420vresearch-articleACS PublicationsCopyright © 1999 American Chemical SocietyRequest reuse permissionsArticle Views8091Altmetric-Citations1586LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Antineoplastic agents,Cancer,Ligands,Platinum,Toxicity Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
Reedijk, J. (1999) · Chemical Reviews · doi:10.1021/cr980422f · Cited by 771
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Improved understanding in platinium antitumour chemistry
Reedijk, J. (1996) · Chemical Communications · doi:10.1039/cc9960000801 · Cited by 589
Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond, É., Faivre, S. J., WOYNAROWSKI, J. M., & Chaney, S. G. (1998) · PubMed · Cited by 520
Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang‐Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., & Ozols, R. F. (1987) · PubMed · Cited by 498
Cited by
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Biological properties of “naked” metal nanoparticles☆
BHATTACHARYA, R., & MUKHERJEE, P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.013 · Cited by 917
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
Metal-based antitumour drugs in the post genomic era
Dyson, P. J., & Sava, G. (2006) · Dalton Transactions · doi:10.1039/b601840h · Cited by 771
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
Reedijk, J. (1999) · Chemical Reviews · doi:10.1021/cr980422f · Cited by 771
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Dhar, S., Liu, Z., Thomale, J., Dai, H., & Lippard, S. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803036e · Cited by 700
Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Wilson, J. J., & Lippard, S. J. (2014) · Chemical Reviews · doi:10.1021/cr4004314 · Cited by 630
Platinum(IV) antitumour compounds: their bioinorganic chemistry
Hall, M. D., & Hambley, T. W. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00026-7 · Cited by 622
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Reedijk, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737293100 · Cited by 617
Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073231f · Cited by 616
Cisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 615
Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 614
Rajendiran, V., Karthik, R., Palaniandavar, M., Stoeckli-Evans, H., Periasamy, V. S., Akbarsha, M. A., Srinag, B. S., & Krishnamurthy, H. (2007) · Inorganic Chemistry · doi:10.1021/ic700755p · Cited by 589
Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?
Gonzalez, V. M., Fuertes, M. A., Alonso, C., & Perez, J. M. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09232-0 · Cited by 578
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Mechanisms of drug release in nanotherapeutic delivery systems
Wong, P. T., & Choi, S. K. (2015) · Chemical Reviews · doi:10.1021/cr5004634 · Cited by 507
Design and development of polymeric micelles with cleavable links for intracellular drug delivery
Wei, H., Zhuo, R.-X., & Zhang, X.-Z. (2013) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2012.07.002 · Cited by 474
Application of ferrocene and its derivatives in cancer research
Ornelas, C. (2011) · New Journal of Chemistry · doi:10.1039/c1nj20172g · Cited by 473
Ruthenium complexes as antimicrobial agents
Li, F., Collins, J. G., & Keene, F. R. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00343h · Cited by 467
Metal complex interactions with DNA
Pages, B. J., Ang, D. L., Wright, E. P., & Aldrich-Wright, J. R. (2015) · Dalton Transactions · doi:10.1039/c4dt02700k · Cited by 459
Therrien, B., Süss‐Fink, G., Govindaswamy, P., Renfrew, A. K., & Dyson, P. J. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800186 · Cited by 446
Porous Hollow Fe3O4 Nanoparticles for Targeted Delivery and Controlled Release of Cisplatin
Cheng, K., Peng, S., Xu, C., & Sun, S. (2009) · Journal of the American Chemical Society · doi:10.1021/ja903300f · Cited by 438
Nepali, K., Sharma, S., Sharma, M., Bedi, P. M. S., & Dhar, K. L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.018 · Cited by 435
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0769 · Cited by 431
Lazarević, T., Rilak, A., & Bugarčić, Ž. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.007 · Cited by 428
Metal based drugs: from serendipity to design
Fricker, S. P. (2007) · Dalton Transactions · doi:10.1039/b705551j · Cited by 414
Polymer−Cisplatin Conjugate Nanoparticles for Acid-Responsive Drug Delivery
Aryal, S., Hu, C.-M. J., & Zhang, L. (2010) · ACS Nano · doi:10.1021/nn9014032 · Cited by 400
Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives
Lee, S. Y., Kim, C. Y., & Nam, T.-G. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s275007 · Cited by 400
The path for metal complexes to a DNA target
Komor, A. C., & Barton, J. K. (2013) · Chemical Communications · doi:10.1039/c3cc00177f · Cited by 384
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Brabec, V., & Nováková, O. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.05.002 · Cited by 384
Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update
dos Santos, N. A. G., Carvalho Rodrigues, M. A., Martins, N. M., & dos Santos, A. C. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0821-7 · Cited by 378
Organometallic ruthenium-based antitumor compounds with novel modes of action
Ang, W. H., Casini, A., Sava, G., & Dyson, P. J. (2011) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2010.11.009 · Cited by 366
Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design
Reedijk, J. (2009) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200900054 · Cited by 343
Recent advances in metal nanoparticles in cancer therapy
Sharma, A., Goyal, A. K., & Rath, G. (2018) · Journal of Drug Targeting · doi:10.1080/1061186x.2017.1400553 · Cited by 341
Advances in cobalt complexes as anticancer agents
Munteanu, C. R., & Suntharalingam, K. (2015) · Dalton Transactions · doi:10.1039/c5dt02101d · Cited by 330
Platinum‐based anticancer agents: Innovative design strategies and biological perspectives
Ho, Y., Au‐Yeung, S. C. F., & To, K. K. W. (2003) · Medicinal Research Reviews · doi:10.1002/med.10038 · Cited by 329
Hydrolysis Theory for Cisplatin and Its Analogues Based on Density Functional Studies
Zhang, Y., Guo, Z., & You, X.-Z. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0023938 · Cited by 317
Ang, W. H., Khalaila, I., Allardyce, C. S., Juillerat-Jeanneret, L., & Dyson, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0432618 · Cited by 314
Inhibitors of the HSP90 Molecular Chaperone: Current Status
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95009-x · Cited by 310
Liposome-based drug co-delivery systems in cancer cells
Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.073 · Cited by 307
Fahrni, C. J. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.02.039 · Cited by 297
Baik, M.-H., Friesner, R. A., & Lippard, S. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036960d · Cited by 293
Bhat, S. S., Kumbhar, A. A., Heptullah, H., Khan, A. A., Gobre, V. V., Gejji, S. P., & Puranik, V. G. (2011) · Inorganic Chemistry · doi:10.1021/ic101534n · Cited by 268
Casini, A., Hartinger, C., Gabbiani, C., Mini, E., Dyson, P. J., Keppler, B. K., & Messori, L. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.11.003 · Cited by 267
Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
Ling, X., Tu, J., Wang, J., Shajii, A., Kong, N., Feng, C., Zhang, Y., Yu, M., Xie, T., Bharwani, Z., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06400 · Cited by 263
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
Chatterjee, S., Kundu, S., Bhattacharyya, A., Hartinger, C. G., & Dyson, P. J. (2008) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-008-0400-9 · Cited by 258
Small molecules regulating reactive oxygen species homeostasis for cancer therapy
Zhang, J., Duan, D., Song, Z., Liu, T., Hou, Y., & Fang, J. (2021) · Medicinal Research Reviews · doi:10.1002/med.21734 · Cited by 184
Shi, Y., Lammers, T., Storm, G., & Hennink, W. E. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201600160 · Cited by 174
Ferroptosis promotes sonodynamic therapy: a platinum( ii )–indocyanine sonosensitizer
Lai, Y., Lu, N., Ouyang, A., Zhang, Q., & Zhang, P. (2022) · Chemical Science · doi:10.1039/d2sc02597c · Cited by 91
Metadata
- Authors
- Wong, E., & Giandomenico, C. M.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-08-17
- Volume
- 99
- Issue
- 9
- Pages
- 2451-2466
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2048168597
- Cited by
- 1,800
- References
- 65
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.